Investigators at the Medical University of South Carolina report in Microbiome that autoantibody production in HIV-positive patients who have undergone antiretroviral therapy is linked to levels of Staphylococcus products in their blood.
Human immunodeficiency virus, or HIV, attacks the immune system, making affected individuals more susceptible to infections. When patients with HIV are treated with antiretroviral therapy (ART), their immune system can recover, but some of them produce self-destructive proteins, or autoantibodies.
HIV-positive, ART-treated patients with high levels of autoantibodies also have increased levels of bacteria (Staphylococcus aureus) products in their blood, according to a recent article by Jiang et al in Microbiome.
Credit: Frank DeLeo, National Institute of Allergy and Infectious Diseases (NIAID)
Instead of attacking foreign invaders such as bacteria or viruses, some autoantibodies attack the body's own cells. This is known as autoimmunity. We all produce low levels of autoantibodies. However, when they are produced persistently at high levels, autoimmunity may occur.
In an article in Microbiome, Wei Jiang, M.D., associate professor in the Department of Microbiology and Immunology at the Medical University of South Carolina (MUSC), and her team report that HIV-positive, ART-treated patients with high levels of autoantibodies also have increased levels of bacteria (Staphylococcus aureus) products in their blood.
The MUSC study compared autoantibody production in HIV-positive patients and healthy individuals before and after receiving a seasonal flu vaccine. Patients provided blood samples before vaccination and one and two weeks after. The blood samples were tested using a 125-autoantibody array panel.
The autoimmune response in the HIV-positive patients was linked to the presence of Staphylococcus aureus products in the blood. This is the same bacteria responsible for skin staph infections. Some HIV-positive patients have a higher baseline level of these bacterial products in their system. The team examined other strains of bacteria but linked only Staphylococcus aureus to autoantibody production in HIV-positive individuals.
A "leaky gut" could explain the increased level of Staphylococcus products in the blood of HIV-positive patients.
In patients with "leaky gut," the intestinal lining is weakened, enabling bacteria and toxic products in the gut to enter the bloodstream, where they become vulnerable to the immune system. The immune system's attacks on these bacteria could also injure the body's own tissues.
A "leaky gut" is associated with persistent inflammation and several chronic illnesses, including HIV, irritable bowel syndrome, celiac disease, and type 1 diabetes.
To verify their findings, Jiang and her team injected heat-killed Staphylococcus bacteria into healthy mice and found that they did in fact stimulate autoantibody production.
"We used animals to verify what we found in humans," explains Jiang. "We saw that the level of Staphylococcus product was correlated with autoantibody production in HIV patients, and we hypothesized that these bacteria induced autoantibodies, so we tested our hypothesis in mice."
The mouse studies were supported by voucher funding from the South Carolina Clinical & Translational Research (SCTR) Institute, an NIH-funded Clinical and Translational Science Awards hub at MUSC.
The ability to further explore clinical findings in an animal model was crucial to this study. The mouse study showed that injection of Staphylococcus bacteria stimulates autoantibody production.
"We are now studying which Staphylococcus products are active in autoantibody production in mice," says Jiang. "It may be possible to design an inhibitor to block these bacteria from activating the immune cells."
Going forward, Jiang and her team hope to design a drug that inhibits Staphylococcus to help prevent autoimmunity in HIV-positive patients receiving ART.
Founded in 1824 in Charleston, The Medical University of South Carolina is the oldest medical school in the South. Today, MUSC continues the tradition of excellence in education, research, and patient care. MUSC educates and trains more than 3,000 students and residents, and has nearly 13,000 employees, including approximately 1,500 faculty members. As the largest non-federal employer in Charleston, the university and its affiliates have collective annual budgets in excess of $2.2 billion. MUSC operates a 700-bed medical center, which includes a nationally recognized Children's Hospital, the Ashley River Tower (cardiovascular, digestive disease, and surgical oncology), Hollings Cancer Center (a National Cancer Institute-designated center) Level I Trauma Center, and Institute of Psychiatry. For more information on academic programs or clinical services, visit musc.edu. For more information on hospital patient services, visit muschealth.org.
The South Carolina Clinical & Translational Research (SCTR) Institute, a National Institutes of Health Clinical and Translational Science Awards hub, is the catalyst for changing the culture of biomedical research, facilitating sharing of resources and expertise, and streamlining research-related processes to bring about large-scale, change in the clinical and translational research efforts in South Carolina. Our vision is to improve health outcomes and quality of life for the population through discoveries translated into evidence-based practice.
Heather Woolwine | EurekAlert!
Shipment tracking for "fat parcels" in the body
14.10.2019 | Rheinische Friedrich-Wilhelms-Universität Bonn
Antibody-based eye drops show promise for treating dry eye disease
14.10.2019 | University of Illinois at Chicago
A new research project at the TH Mittelhessen focusses on the development of a novel light weight design concept for leisure boats and yachts. Professor Stephan Marzi from the THM Institute of Mechanics and Materials collaborates with Krake Catamarane, which is a shipyard located in Apolda, Thuringia.
The project is set up in an international cooperation with Professor Anders Biel from Karlstad University in Sweden and the Swedish company Lamera from...
Superconductivity has fascinated scientists for many years since it offers the potential to revolutionize current technologies. Materials only become superconductors - meaning that electrons can travel in them with no resistance - at very low temperatures. These days, this unique zero resistance superconductivity is commonly found in a number of technologies, such as magnetic resonance imaging (MRI).
Future technologies, however, will harness the total synchrony of electronic behavior in superconductors - a property called the phase. There is currently a...
How do some neutron stars become the strongest magnets in the Universe? A German-British team of astrophysicists has found a possible answer to the question of how these so-called magnetars form. Researchers from Heidelberg, Garching, and Oxford used large computer simulations to demonstrate how the merger of two stars creates strong magnetic fields. If such stars explode in supernovae, magnetars could result.
How Do the Strongest Magnets in the Universe Form?
A hot, molten Earth would be around 5% larger than its solid counterpart. This is the result of a study led by researchers at the University of Bern. The difference between molten and solid rocky planets is important for the search of Earth-like worlds beyond our Solar System and the understanding of Earth itself.
Rocky exoplanets that are around Earth-size are comparatively small, which makes them incredibly difficult to detect and characterise using telescopes. What...
Scientists at the Max Planck Institute for Chemical Physics of Solids in Dresden, Princeton University, the University of Illinois at Urbana-Champaign, and the University of the Chinese Academy of Sciences have spotted a famously elusive particle: The axion – first predicted 42 years ago as an elementary particle in extensions of the standard model of particle physics.
The team found signatures of axion particles composed of Weyl-type electrons (Weyl fermions) in the correlated Weyl semimetal (TaSe₄)₂I. At room temperature,...
02.10.2019 | Event News
02.10.2019 | Event News
19.09.2019 | Event News
14.10.2019 | Physics and Astronomy
14.10.2019 | Earth Sciences
14.10.2019 | Health and Medicine